Invention Grant
- Patent Title: Uses of salt-inducible kinase (SIK) inhibitors
-
Application No.: US15847856Application Date: 2017-12-19
-
Publication No.: US10265321B2Publication Date: 2019-04-23
- Inventor: Alykhan Shamji , Thomas Sundberg , Nathanael S. Gray , Ramnik Xavier , Stuart L. Schreiber , Hwan Geun Choi , Yanke Liang
- Applicant: Dana-Farber Cancer Institute, Inc. , The Broad Institute, Inc. , President and Fellows of Harvard College , The General Hospital Corporation
- Applicant Address: US MA Boston US MA Cambridge US MA Cambridge US MA Boston
- Assignee: Dana-Farber Cancer Institute, Inc.,The Broad Institute, Inc.,President and Fellows of Harvard College,The General Hospital Corporation
- Current Assignee: Dana-Farber Cancer Institute, Inc.,The Broad Institute, Inc.,President and Fellows of Harvard College,The General Hospital Corporation
- Current Assignee Address: US MA Boston US MA Cambridge US MA Cambridge US MA Boston
- Agency: Wolf, Greenfield & Sacks, P.C.
- Main IPC: A61K31/5377
- IPC: A61K31/5377 ; A61K31/519 ; A61K45/06 ; A61K31/506
Abstract:
The present disclosure provides methods of treating and/or preventing inflammatory bowel disease (IBD) and graft-versus-host disease (GVHD) using salt-inducible kinase (SIK) inhibitors, such as macrocyclic SIK inhibitors of Formula (I), imidazolyl SIK inhibitors of Formula (II), and urea and carbamate SIK inhibitors of Formula (III-A) (e.g., urea and carbamate SIK inhibitors of Formula (III)).
Public/Granted literature
- US20180221379A1 USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS Public/Granted day:2018-08-09
Information query
IPC分类:
